ABA Autism denied as not FDA-approved for this use by Aetna?

Aetna's specific coverage criteria for aba autism are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Denied ABA Therapy as "Not FDA-Approved" — and Why You Can Appeal

Applied Behavior Analysis (ABA) is a behavioral health service, not a drug, so it does not require FDA approval the way a pharmaceutical does. When Aetna issues a "not FDA-approved" denial for ABA therapy, they are typically applying a policy framework that classifies the intervention under an investigational or experimental standard rather than a drug-approval standard. This framing is legally and clinically contestable: ABA is recognized by major professional bodies including the American Academy of Pediatrics, the American Psychological Association, and the U.S. Surgeon General as an evidence-based treatment for Autism Spectrum Disorder (ASD). Federal law — specifically the Mental Health Parity and Addiction Equity Act (MHPAEA) — also requires that behavioral health benefits be administered no more restrictively than comparable medical or surgical benefits.

## Federal Appeal Framework

You have enforceable rights under federal law:

• ACA §2719 / External Review: Most fully-insured plans must offer independent external review. You have approximately four months (180 days) from the denial date to request external review. An expedited track is available when standard timelines would seriously jeopardize health.
• ERISA §503: If your plan is employer-sponsored and self-funded, you are entitled to a full-and-fair internal review, a written decision with specific reasons, and ultimately federal-court review.
• MHPAEA: Request Aetna's written "non-quantitative treatment limitation" (NQTL) analysis explaining why ABA is held to a standard not applied to analogous medical services.

## Documentation to Gather

• Diagnosis confirmation: A licensed clinician's written ASD diagnosis referencing the diagnostic criteria (DSM-5 or equivalent).
• Medical-necessity letter: A detailed letter from the treating BCBA or supervising physician explaining why ABA is medically necessary for this individual, the specific treatment goals, and the expected functional outcomes.
• Prior treatment history: Records of any behavioral, developmental, or educational interventions tried previously, with dates and documented outcomes.
• Clinical severity documentation: Current functional assessments, behavior frequency/intensity data, and any standardized rating scales in the chart.
• Insurer's own policy: Obtain Aetna's published Clinical Policy Bulletin for ABA therapy so you can map each stated criterion to the evidence in the chart.

## Criteria-Mapping Structure

Build a table: copy every requirement from Aetna's clinical policy on the left, and answer each one with the specific chart fact on the right. Where the denial letter claims "not FDA-approved," directly rebut with the documented evidence-based and professional-society support for ABA, and cite the MHPAEA parity obligation. Submit this mapping with the appeal letter.